Safety and side effects of cannabidiol, a Cannabis sativa constituent - PubMed (original) (raw)
Review
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Mateus Machado Bergamaschi et al. Curr Drug Saf. 2011.
Abstract
Cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, has multiple pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties. However, little is known about its safety and side effect profile in animals and humans. This review describes in vivo and in vitro reports of CBD administration across a wide range of concentrations, based on reports retrieved from Web of Science, Scielo and Medline. The keywords searched were "cannabinoids", "cannabidiol" and "side effects". Several studies suggest that CBD is non-toxic in non-transformed cells and does not induce changes on food intake, does not induce catalepsy, does not affect physiological parameters (heart rate, blood pressure and body temperature), does not affect gastrointestinal transit and does not alter psychomotor or psychological functions. Also, chronic use and high doses up to 1,500 mg/day of CBD are reportedly well tolerated in humans. Conversely, some studies reported that this cannabinoid can induce some side effects, including inhibition of hepatic drug metabolism, alterations of in vitro cell viability, decreased fertilization capacity, and decreased activities of p-glycoprotein and other drug transporters. Based on recent advances in cannabinoid administration in humans, controlled CBD may be safe in humans and animals. However, further studies are needed to clarify these reported in vitro and in vivo side effects.
Similar articles
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Zuardi AW, et al. Braz J Med Biol Res. 2006 Apr;39(4):421-9. doi: 10.1590/s0100-879x2006000400001. Epub 2006 Apr 3. Braz J Med Biol Res. 2006. PMID: 16612464 Review. - Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW. Zuardi AW. Braz J Psychiatry. 2008 Sep;30(3):271-80. doi: 10.1590/s1516-44462008000300015. Braz J Psychiatry. 2008. PMID: 18833429 Review. - Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Schier AR, et al. Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. doi: 10.1590/s1516-44462012000500008. Braz J Psychiatry. 2012. PMID: 22729452 Review. English, Portuguese. - Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Silvestro S, et al. Molecules. 2019 Apr 12;24(8):1459. doi: 10.3390/molecules24081459. Molecules. 2019. PMID: 31013866 Free PMC article. Review. - Cannabidiol: an overview of some pharmacological aspects.
Mechoulam R, Parker LA, Gallily R. Mechoulam R, et al. J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. doi: 10.1002/j.1552-4604.2002.tb05998.x. J Clin Pharmacol. 2002. PMID: 12412831 Review.
Cited by
- Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo.
Pongking T, Thongpon P, Intuyod K, Klungsaeng S, Thanan R, Chaidee A, Charoenram N, Kongsintaweesuk S, Sakonsinsiri C, Vaeteewoottacharn K, Pinlaor S, Pinlaor P. Pongking T, et al. BMC Complement Med Ther. 2024 Aug 30;24(1):325. doi: 10.1186/s12906-024-04610-2. BMC Complement Med Ther. 2024. PMID: 39215312 Free PMC article. - In vitro Effect of Cannabidiol on Red Blood Cells: Implication in Long-Lasting Pathology Treatment.
Gómez CT, Borda N, Moscovicz F, Fernandez F, Lazarowski A, Auzmendi J. Gómez CT, et al. Curr Pharm Des. 2024;30(28):2222-2228. doi: 10.2174/0113816128287272240529072040. Curr Pharm Des. 2024. PMID: 38874045 - The Development of Cannabinoids as Therapeutic Agents in the United States.
Murray CH, Gannon BM, Winsauer PJ, Cooper ZD, Delatte MS. Murray CH, et al. Pharmacol Rev. 2024 Aug 15;76(5):915-955. doi: 10.1124/pharmrev.123.001121. Pharmacol Rev. 2024. PMID: 38849155 Review. - Protective Effects of Cannabidiol (CBD) against Qxidative Stress, but Not Excitotoxic-Related Neuronal Cell Damage-An In Vitro Study.
Jantas D, Leśkiewicz M, Regulska M, Procner M, Warszyński P, Lasoń W. Jantas D, et al. Biomolecules. 2024 May 9;14(5):564. doi: 10.3390/biom14050564. Biomolecules. 2024. PMID: 38785971 Free PMC article. - Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.
Johnson K, Weldon AJ, Burmeister MA. Johnson K, et al. Front Psychiatry. 2024 Apr 23;15:1386263. doi: 10.3389/fpsyt.2024.1386263. eCollection 2024. Front Psychiatry. 2024. PMID: 38716117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources